Exelixis, inc. EXEL.US Overview
EXEL AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
EXEL Current Performance
-3.33%
Exelixis, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
EXEL Key Information
EXEL Revenue by Segments
Browsing restrictions can be lifted for a fee.
EXEL Net Income
Browsing restrictions can be lifted for a fee.
EXEL Cash Flow
Browsing restrictions can be lifted for a fee.
EXEL Profit Margin
Browsing restrictions can be lifted for a fee.
EXEL PE Ratio River
Browsing restrictions can be lifted for a fee.
EXEL Financial Forecast
Browsing restrictions can be lifted for a fee.
EXEL Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
EXEL Profile
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Price of EXEL
EXEL FAQ
When is EXEL's latest earnings report released?
The most recent financial report for Exelixis, inc. (EXEL) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EXEL's short-term business performance and financial health. For the latest updates on EXEL's earnings releases, visit this page regularly.
Where does EXEL fall in the P/E River chart?
According to historical valuation range analysis, Exelixis, inc. (EXEL)'s current price-to-earnings (P/E) ratio is 15.66, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of EXEL?
According to the latest financial report, Exelixis, inc. (EXEL) reported an Operating Profit of 186.86M with an Operating Margin of 33.64% this period, representing a growth of 534.24% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is EXEL's revenue growth?
In the latest financial report, Exelixis, inc. (EXEL) announced revenue of 555.45M, with a Year-Over-Year growth rate of 30.62%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does EXEL have?
At the end of the period, Exelixis, inc. (EXEL) held Total Cash and Cash Equivalents of 183.75M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does EXEL go with three margins increasing?
In the latest report, Exelixis, inc. (EXEL) achieved the “three margins increasing” benchmark, with a gross margin of 96.5%%, operating margin of 33.64%%, and net margin of 28.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess EXEL's profit trajectory and future growth potential.
Is EXEL's EPS continuing to grow?
According to the past four quarterly reports, Exelixis, inc. (EXEL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.57. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of EXEL?
Exelixis, inc. (EXEL)'s Free Cash Flow (FCF) for the period is 208.49M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 252.58% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.